Recombinant DLL3 (Rovalpituzumab Biosimilar) antibody

Catalog No. ABIN7581372

This Human Monoclonal antibody specifically detects DLL3 (Rovalpituzumab Biosimilar) in FACS, ELISA, BLI, Func and SPR. It exhibits reactivity toward Human.

Quick Overview for Recombinant DLL3 (Rovalpituzumab Biosimilar) antibody (ABIN7581372)

Target: DLL3 (Rovalpituzumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Human

Clonality: Monoclonal

Conjugate: This DLL3 (Rovalpituzumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), ELISA, Bio-Layer Interferometry (BLI), Functional Studies (Func), Surface Plasmon Resonance (SPR)

Product Details anti-DLL3 (Rovalpituzumab Biosimilar) Antibody

Expression System: CHO Cells

Purpose: Anti-DLL3 Reference Antibody (rovalpituzumab)

Sequence: QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYGMNWVRQA PGQGLEWMGW INTYTGEPTY ADDFKGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARIG DSSPSDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPG,EIVMTQSPAT LSVSPGERAT LSCKASQSVS NDVVWYQQKP GQAPRLLIYY ASNRYTGIPA RFSGSGSGTE FTLTISSLQS EDFAVYYCQQ DYTSPWTFGQ GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC

Characteristics: Anti-DLL3 Reference Antibody (rovalpituzumab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.

Purity: >95 %

Isotype: IgG1

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Therapeutic Agents by Target and Mechanism: DLL3 inhibitors

Conditions: Cancer Lung Cancer (advanced small cell)

Restrictions: For Research Use only

Handling

Format: Lyophilized

Concentration: 1 mg/mL

Buffer: 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2

Storage: 4 °C,-80 °C

Storage Comment: +4°C,-80°C

Target Details for DLL3 (Rovalpituzumab Biosimilar)

Target: DLL3 (Rovalpituzumab Biosimilar)

Target Type: Biosimilar

Background: Synonyms: Delta Like Canonical Notch Ligand 3, D3

Molecular Weight: 145.5 kDa

UniProt: Q9NYJ7